CVS Health plans to split into two publicly traded companies in the first half of 2028, separating its pharmacy and insurance/PBM businesses
CVS Health announced on November 4, 2026, that it plans to split the company into two independent publicly traded companies. The transaction is expected to be completed in the first half of 2028 and is intended to be tax-free to CVS Health and its shareholders, subject to conditions including final approval by the board of directors, the effectiveness of the Form 10 filing with the U.S. Securities and Exchange Commission, and confirmation of the tax treatment.
One company, which will continue to be called CVS Health during the transition period, will retain Aetna insurance, CVS Caremark pharmacy benefit management (PBM), CVS Specialty, Oak Street Health and Signify Health. The other will be named CVS Pharmacy and will take on about 9,000 CVS stores, mail-order pharmacy, MinuteClinic, including virtual care, and the Health100 technology services business. Current Chairman and Chief Executive Officer David Joyner will lead the healthcare solutions company, and Group President Prem Shah will become chief executive officer of CVS Pharmacy. After completion, shareholders will hold shares in both companies.
Caremark is one of the three largest pharmacy benefit managers in the United States. The split will reverse the company’s earlier strategy of integrating retail pharmacies, insurance and PBM through acquisitions, including the 2007 merger with Caremark and the approximately $78 billion acquisition of Aetna in 2018.
Original source:
Title: CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare Publisher: CVS Health (via PR Newswire) Publication date: 2026-11-04 URL: https://www.prnewswire.com/news-releases/cvs-health-announces-intent-to-create-two-distinct-leaders-in-healthcare-302928585.html Source nature: official company press release Verification status: relevant paragraphs were actually read in this instance, verification date 2026-11-04 Supported content: supports all key facts in the body, including the intent to split, the business division between the two companies, about 9,000 stores, the Aetna and Caremark assignments, the timeline (first half of 2028), the tax-free intent, leadership arrangements and conditions
ABAB AI Insight
After CVS merged with Caremark in 2007 and acquired Aetna in 2018, it built a vertically integrated group structure spanning retail pharmacies, insurance and PBM. In recent years, the company has faced cost pressure, volatility in Aetna’s performance and regulatory attention to vertical integration. In 2024, it explored options including a split. This announcement is seen as a strategic shift away from the view that bigger is better and toward a more focused business structure.
After the split, CVS Pharmacy will operate as an independent retail and community healthcare company, facing the general profit pressure and competition in the pharmacy industry. The company that retains Aetna and Caremark will be closer to the model of peers such as UnitedHealth and Cigna, which also have insurance, PBM and specialty businesses. The two companies are expected to maintain investment-grade ratings at the time of the split and have independent investment and dividend capabilities.
The transaction still needs regulatory and tax procedures to be completed, and details on the allocation of assets, debt and costs have not been disclosed. Points to watch are the financial separation details disclosed in the Form 10 filing, the valuation performance of the two companies after their independent listings, and the specific arrangements for future commercial relations between the pharmacy and PBM businesses.
ABAB News · Cognitive Law
The company’s announced intent to split and the expected completion time are plans, and the transaction can only proceed after board approval, the Form 10 becoming effective and tax confirmation.
After the vertically integrated group is split, the original internal trading relationship will become an external contractual arrangement between independent companies, and pricing and terms will need to be renegotiated.